Accretion Pharmaceuticals Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹0(0.00%)
Premium (ELP)
Accretion Pharmaceuticals Limited's successfully completed its Initial Public Offering and commenced trading on May 21, 2025 at the NSE exchange. The company raised 29,46,000 Shares through this public offering, comprising 29,46,000 Shares in fresh capital.
The IPO was priced within the band of ₹101 to ₹101, with minimum application lots of 1200 shares. The offering attracted significant investor interest during its subscription period from May 14, 2025 to May 16, 2025.
Share allotment was finalized on May 19, 2025, distributing equity to successful applicants. The stock's subsequent listing marked a significant milestone in the company's corporate history, providing public market liquidity to shareholders.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Accretion Pharmaceuticals Limited, founded in 2012 and based in Ahmedabad-Sanand, Gujarat, is a pharmaceutical company active in formulations and contract manufacturing with 83 employees as of January 2025. The company offers a wide range of products including tablets, capsules, syrups, ointments, creams, medicated shampoos, dusting powders, and ayurvedic wellness products, and also provides third-party manufacturing services. The proposed fund usage mainly focuses on growth capex such as facility upgrades and new machinery to increase capacity and support exports to 20+ countries, along with working capital needs, limited debt repayment, and flexibility for general purposes, helping the company scale operations, maintain quality standards, improve liquidity, and support future expansion opportunities.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Experienced Leadership: Run by promoters and management with strong industry expertise.
- Strong Relationships: Long-standing client & supplier partnerships support business stability.
- Quality Focus: ISO-certified systems ensure high-quality pharmaceutical & healthcare products.
- Ongoing Legal Cases: Current court proceedings could harm the company’s reputation and business performance.
- Changing Regulations: Not keeping up with updated pharmaceutical laws may lead to disruptions and affect business operations.
- Regulatory Checks: Unfavorable inspection results from authorities or clients could lead to penalties or damage the company’s image.
- Mr. Mayur Popatlal Sojitra
- Mr. Harshad Nanubhai Rathod
- Mr. Vivek Ashok Kumar Patel
- Mr. Hardik Mukundbhai Prajapati.
Accretion Pharmaceuticals Limited
Kfin Technologies Limited